Ropsacitinib (PF-06826647; Tyk2-IN-8; PF06826647) is a novel, selective and orally bioavailable TYK2 (tyrosine kinase) inhibitor with potential anti-inflammatory activity. It inhibits TYK2 with IC50 of 17 nM, and binds to TYK2 catalytically active JH1 domain with an IC50 of 17 nM, and has the potential to be used in the treatment of psoriasis.

纯度：≥98%

CAS：2127109-84-4